No Drop in All-Cause Mortality With ICD in Systolic Heart Failure

This article originally appeared here.
Share this content:
No Drop in All-Cause Mortality With ICD in Systolic Heart Failure
No Drop in All-Cause Mortality With ICD in Systolic Heart Failure

MONDAY, Aug. 29, 2016 (HealthDay News) -- For patients with symptomatic systolic heart failure not caused by coronary artery disease, an implantable cardioverter-defibrillator (ICD) does not reduce the risk of all-cause mortality, according to a study published online Aug. 28 in the New England Journal of Medicine. The research was published to coincide with the annual European Society of Cardiology Congress, held from Aug. 27 to 31 in Rome.

Lars Køber, M.D., from University Hospital in Copenhagen, Demark, and colleagues conducted a randomized controlled trial involving patients with symptomatic systolic heart failure not caused by coronary artery disease who were assigned to receive an ICD (556 patients) or usual clinical care (560 patients).

The researchers found that the primary outcome of death from any cause occurred in 21.6 percent of the ICD group and 23.4 percent of the control group, after a median follow-up period of 67.6 months (hazard ratio, 0.87; 95 percent confidence interval, 0.68 to 1.12). Sudden cardiac death occurred in 4.3 and 8.2 percent of the ICD and control groups, respectively (hazard ratio, 0.50; 95 percent confidence interval, 0.31 to 0.82). Device infection occurred in 4.9 and 3.6 percent of patients in the ICD and control groups, respectively (P = 0.029).

"In this trial, prophylactic ICD implantation in patients with symptomatic systolic heart failure not caused by coronary artery disease was not associated with a significantly lower long-term rate of death from any cause than was usual clinical care," the authors write.

The study was funded by Medtronic.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »